Ogier advises NovoCure Limited on its IPO on NASDAQ

Ogier advises NovoCure Limited on its IPO on NASDAQ

Ogier in Jersey have recently advised cancer treatment company NovoCure Limited on its IPO on NASDAQ.   

The IPO raised US$165 million for NovoCure by the sale of 7,500,000 shares at a price of US$22 per share.  

NovoCure will trade under the symbol NVCR on NASDAQ.

Domiciled in Jersey, NovoCure is a commercial-stage oncology company developing a therapy called Tumor Treating Fields, which destroys cancer cells in tumors using alternating electric fields. The company expects to use the proceeds from the IPO for clinical trials, research and development, commercialisation efforts and working capital.

The Ogier team was led by Simon Schilder (Partner), with Dilmun Leach (Senior Associate) and Ian Clark (Associate) and worked alongside Proskauer Rose LLP in New York in advising NovoCure on its IPO. Perella Weinberg Partners LP were Novocure’s financial adviser. J.P. Morgan Securities LLC, Deutsche Bank Securities and Evercore Group LLC acted as joint book-running managers, Wells Fargo Securities LLC acted as lead manager and JMP Securities LLC and Wedbush PacGrow acted as co-managers. Davis Polk & Wardwell LLP acted as counsel to the underwriters.

Commenting on the deal, Simon Schilder said “We are delighted to have advised long standing client NovoCure on its IPO on NASDAQ”.